A framework for assessing the impact of accelerated approval.
Saved in:
| Title: | A framework for assessing the impact of accelerated approval. |
|---|---|
| Authors: | Gould AL; Methodology Research, BARDS, Merck & Co., Inc., Kenilworth, New Jersey, United States of America., Campbell RK; Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, Rhode Island, United States of America., Loewy JW; DataForethought, Winchester, Massachusetts, United States of America., Beckman RA; Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC, United States of America., Dey J; Data and Statistical Sciences, AbbVie, North Chicago, Illinois, United States of America., Schiel A; Department for Pharmacoeconomics, Norwegian Medicines Agency, Oslo, Norway., Burman CF; Data Science & AI, AstraZeneca R&D, Gothenburg, Sweden., Zhou J; Xcovery Pharmaceuticals, Palm Beach Gardens, Florida, United States of America., Antonijevic Z; Abond CRO, Allendale, Michigan, United States of America., Miller ER; Independent Biostatistical Consultant, Middletown Twp, Pennsylvania, United States of America., Tang R; Methodology and Data Visualization, Biostatistics Department, Servier Pharmaceuticals US, Boston, Massachusetts, United States of America. |
| Source: | PloS one [PLoS One] 2022 Jun 24; Vol. 17 (6), pp. e0265712. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
